---
layout: default
title: Milrinone
parent: Low Evidence (L5)
nav_order: 669
evidence_level: L5
indication_count: 10
---

# Milrinone
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Milrinone: From Heart Failure to Alopecia

## One-Sentence Summary

Milrinone is an injectable PDE3 inhibitor. It is known for short-term intravenous use in acute decompensated heart failure, although the Singapore license text supplied here does not state an indication.
The TxGNN model predicts it may be effective for **alopecia**, but **0 clinical trials** and **0 publications** support this direction.
The prediction rests on network-based scoring alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the Singapore license data. The heart-failure use comes from the pack's mechanistic notes on other predictions. |
| Predicted New Indication | Alopecia |
| TxGNN Prediction Score | 99.91% (model rank 1864) |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the pack. Milrinone is a PDE3 inhibitor, so it raises cAMP and produces inotropy and vasodilation. Its efficacy in heart failure is established.

One speculative link to alopecia is that cAMP-driven vasodilation might improve blood flow around hair follicles, by analogy with minoxidil. No trial, publication or preclinical data supplied here supports this. The high score most likely reflects proximity to other hair-loss nodes in the knowledge graph.

The route also does not fit. The only Singapore product is an intravenous concentrate. Systemic milrinone carries arrhythmia and hypotension risk, which is hard to justify for a cosmetic or dermatologic condition.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Singapore Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| SIN15249P | MILRINONE-BAXTER CONCENTRATED SOLUTION FOR INJECTION 10MG/10ML (Baxter Pharmaceuticals India Private Limited) | Injection, solution, concentrate | Not stated in supplied data |

---

## Safety Considerations

Please refer to the package insert for safety information.

The pack's rationale notes that systemic IV milrinone carries arrhythmia and hypotension risk. No drug-interaction records were found.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The alopecia prediction is model-only (L5). No trials or literature were found, and the plausible mechanism is speculative. The injectable-only product also does not suit a dermatologic use. The related hair-disorder predictions (hypotrichosis, diffuse alopecia areata) are likewise L5 with no supporting evidence.

**To proceed, the following is needed:**
- Any preclinical or clinical evidence linking PDE3 inhibition to hair growth
- A feasible route of administration, such as a topical formulation, since only an injectable is registered in Singapore
- The HSA package insert, to obtain warnings, contraindications and the approved indication
- Mechanism-of-action data from DrugBank

For context, the pack's better-supported milrinone predictions are congestive heart failure (L2, Proceed with Guardrails) and acute pulmonary heart disease (L4, Research Question). Only part of the trial list was supplied for them.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

